NCT05979220View on ClinicalTrials.gov

Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

178

Participants

Timeline

Start Date

December 1, 2023

Primary Completion Date

June 30, 2024

Study Completion Date

June 30, 2028

Conditions

Breast Cancer

Interventions

DRUG

Dalpiciclib combined with Letrozole

A multicenter, single arm, prospective Phase II clinical study

Trial Locations (1)

Unknown

West China Hospital, Sichuan University, Chengdu

All Listed Sponsors

lead

Shuangyue Liu

OTHER

NCT05979220 - Study of Dalpiciclib Combined With Letrozole in the Maintenance Treatment of HR Positive and HER2 Negative Metastatic Breast Cancer After First-line Chemotherapy | Biotech Hunter | Biotech Hunter